CJC-1295 No DAC Explained: What It Means for UK Peptide Research 2026 | Daxer Labs

Quick answer: CJC-1295 no DAC is the short-acting form of the growth-hormone-releasing hormone (GHRH) analogue CJC-1295 — the version without the Drug Affinity Complex (DAC) that extends the long-acting variant's circulation time. In published research, the no-DAC form is associated with an approximate 30-minute half-life, compared with roughly 6 to 8 days for CJC-1295 with DAC. Daxer Labs stocks the no-DAC form combined with Ipamorelin, the pairing most frequently referenced in UK peptide research literature. This guide explains what "DAC" means, how the two forms differ structurally, and what that means for anyone reviewing CJC-1295 research.

What Does "DAC" Actually Stand For?

DAC stands for Drug Affinity Complex — a chemical modification added to the CJC-1295 peptide chain via a lysine linker. The complex is designed to bind reversibly to albumin, the most abundant protein circulating in blood plasma. This albumin-binding mechanism is what gives CJC-1295 DAC its extended circulation time, protecting the peptide from rapid enzymatic breakdown. CJC-1295 no DAC omits this modification entirely, leaving a peptide structurally closer to the body's naturally occurring GHRH(1-29) sequence.

Because the no-DAC form doesn't carry this albumin-binding complex, it behaves in research models much more like endogenous GHRH — a short, pulsatile signal rather than a sustained one. This structural distinction is the single most important thing to understand before comparing the two forms in any research context.

CJC-1295 No DAC vs CJC-1295 DAC — the Key Structural Difference

The two forms share the same core GHRH(1-29) analogue sequence, but differ in one critical respect:

• No DAC: closely mirrors native GHRH(1-29), with no albumin-binding modification attached

• DAC: includes a lysine-linked Drug Affinity Complex that binds reversibly to serum albumin

• No DAC: cleared from circulation relatively quickly once introduced into a research system

• DAC: remains detectable in circulation for a substantially longer window due to albumin protection

Both forms act on the same GHRH receptor pathway. The difference is entirely pharmacokinetic — how long the compound remains active in circulation — rather than a difference in mechanism of action.

Half-Life and Circulation Time in Published Research

Half-life is the most frequently cited distinction between the two forms in peptide research literature:

• CJC-1295 (no DAC): approximately 30 minutes

• CJC-1295 with DAC: approximately 6 to 8 days

This difference in circulation time is why researchers select one form over the other depending on study design — whether the protocol calls for a brief, pulsatile signal that mirrors natural GHRH release, or a sustained, longer-acting exposure profile. Neither form is inherently "better"; they serve different research questions and different experimental designs.

Why Daxer Labs Stocks the No-DAC Form Paired With Ipamorelin

Daxer Labs' catalogue includes the IPAMORELIN/CJC 1295 - no DAC combination product, reflecting the pairing most commonly referenced in UK-based peptide research: a GHRP-class compound (Ipamorelin) alongside a short-acting GHRH analogue (CJC-1295 no DAC). This combination is frequently discussed in the literature because the two compounds act on different receptor pathways — Ipamorelin on the ghrelin/GHS-R1a receptor, and CJC-1295 no DAC on the GHRH receptor — a dual-pathway mechanism researchers often study for pulsatile signalling behaviour.

Daxer Labs' current catalogue does not list a standalone long-acting DAC variant — only the no-DAC form, supplied as part of the combined Ipamorelin/CJC-1295 product, with full batch documentation included.

Research Applications Explored in the Literature

Published and preclinical research involving CJC-1295 no DAC and related GHRH analogues has explored themes including:

• Pulsatile growth hormone secretion signalling models

• Comparative pharmacokinetics between short- and long-acting GHRH analogues

• Receptor-binding studies at the GHRH receptor

• Combination-protocol research alongside GHRP-class compounds such as Ipamorelin

These are areas of academic and laboratory interest, not indications for use. Nothing in this article should be interpreted as guidance for administering these compounds to humans or animals.

Storage, Handling and Purity Verification

Like all lyophilised research peptides, CJC-1295 no DAC requires careful storage before and after reconstitution to preserve integrity. For step-by-step guidance, see Daxer Labs' How to Store Research Peptides UK and How to Reconstitute Research Peptides UK guides. Every batch shipped by Daxer Labs is accompanied by a Certificate of Analysis; for background on how purity is verified, see How Is Peptide Purity Verified with HPLC Testing?.

Frequently Asked Questions

What does "no DAC" mean in CJC-1295?

"No DAC" means the peptide does not include the Drug Affinity Complex, a lysine-linked chemical addition that binds to albumin and extends circulation time. CJC-1295 no DAC is the short-acting form, structurally closer to native GHRH(1-29).

What is the approximate half-life of CJC-1295 no DAC?

Published research places the half-life of CJC-1295 no DAC at approximately 30 minutes, compared with roughly 6 to 8 days for the DAC-modified form.

Is CJC-1295 no DAC legal to buy in the UK?

Yes. CJC-1295 is not scheduled under the Misuse of Drugs Act 1971, and can be lawfully bought, sold, and possessed in the UK when supplied and marketed strictly for laboratory research, with no medical claims or marketing for human use.

Why is CJC-1295 no DAC often paired with Ipamorelin in research?

The two compounds act on different receptor pathways — Ipamorelin on the ghrelin/GHS-R1a receptor and CJC-1295 no DAC on the GHRH receptor — a combination frequently referenced in pulsatile growth hormone signalling research.

Does Daxer Labs sell CJC-1295 DAC or only the no-DAC form?

Daxer Labs' current catalogue stocks the no-DAC form as part of the combined IPAMORELIN/CJC 1295 - no DAC product; it does not list a standalone long-acting DAC variant.

Important: This article is written for laboratory research and educational purposes only. Daxer Labs supplies all compounds strictly for in-vitro laboratory research, not for human or animal use, and nothing in this guide should be read as dosing or administration guidance. All products are labelled Research Use Only (RUO) and are not intended for diagnostic, therapeutic, or any other use in humans or animals.

Researchers sourcing CJC-1295 no DAC for laboratory use can view full specifications, batch documentation, and Certificates of Analysis for the IPAMORELIN/CJC 1295 - no DAC on the Daxer Labs product page.